A 2024 review of GLP-1-based therapies concluded that reductions in muscle volume may be broadly proportionate to the amount of weight lost and may occur alongside reduced muscle fat infiltration and improved metabolic quality
Mechanism of Action: Triple Receptor Agonist Retatrutide is a synthetic peptide that activates three key metabolic receptors: GLP-1 (Glucagon-Like Peptide-1) Enhances insulin secretion, suppresses appetite, delays gastric emptying GIP (Glucose-Dependent Insulinotropic Polypeptide) Boosts insulin response, improves insulin sensitivity, may support lipid metabolism Glucagon Receptor (GCGR) Elevates energy expenditure, promotes fat oxidation, and may reduce liver fat This triple agonist profile delivers synergistic effects on glycemic control, fat loss, and metabolic health, making Retatrutide the most advanced incretin-based peptide in development
Longer peptides have more opportunities for synthesis errors, degradation, and aggregation
Yes, the likelihood of side effects often goes up with higher doses
How do cost and access compare for mochi vs ro
Case 1 has Hashimotos thyroiditis, with high levels of anti-TPO antibodies and low IgE which suggest CSU aiTIIb
